I am a
Home I AM A Search Login

Papers of the Week


2021 Feb 01


Bioorg Med Chem Lett

Dioxotriazine derivatives as a new class of P2X receptor antagonists: Identification of a lead and initial SAR studies.

Authors

Kai H, Horiguchi T, Kameyama T, Asahi K, Endoh T, Jikihara S, Hasegawa T, Tanaka S, Nozu A, Takeyama C, Tomari M, Takahashi F, Tamura N, Yagi S, Itoh T, Isou Y
Bioorg Med Chem Lett. 2021 Feb 01:127833.
PMID: 33540044.

Abstract

P2X receptor is an ATP-gated ion channel, mainly localized on peripheral sensory neurons. Currently, several clinical trials are being conducted with P2X receptor antagonists for the treatment of chronic pain or cough. To identify a P2X lead compound, we reexamined the HTS evaluation compounds and selected dioxotriazine derivatives from which we identified a hit compound. As a result of the hit-to-lead SAR, we obtained lead compound 1 which had a moderate inhibitory effect on P2X receptors (IC, 128 nM). Further improvement of the potency and PK profiles of this lead compound finally led to the selected compound 74 (P2X IC, 16.1 nM; P2X IC, 2931 nM), which demonstrated a strong analgesic effect against allodynia on oral administration in the rat partial sciatic nerve ligation model of neuropathic pain (ED, 3.1 mg/kg).